Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

BACKGROUND: The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, extending...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Sung Yong, Kim, Won Seog, Kim, Jin Seok, Kim, Seok Jin, Yoon, Dok Hyun, Yang, Deok-Hwan, Lee, Won Sik, Kim, Hyo Jung, Yhim, Ho-Young, Jeong, Seong Hyun, Won, Jong Ho, Lee, Suee, Kong, Jee Hyun, Lim, Sung-Nam, Ji, Jun Ho, Kwon, Kyung A., Lee, Gyeong-Won, Lee, Jae Hoon, Lee, Ho Sup, Shin, Ho-Jin, Suh, Cheolwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796378/
https://www.ncbi.nlm.nih.gov/pubmed/31619290
http://dx.doi.org/10.1186/s40880-019-0403-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796378/
https://www.ncbi.nlm.nih.gov/pubmed/31619290
http://dx.doi.org/10.1186/s40880-019-0403-7

Ejemplares similares